Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors
Guo, Hua, Ding, Qingqing, Gong, Yun, Gilcrease, Michael Z., Zhao, Min, Zhao, Jun, Sui, Dawen, Wu, Yun, Chen, Hui, Liu, Hui, Zhang, Jinxia, Resetkova, Erika, Moulder, Stacy L., Wang, Wei-Lien, Huo, LeiVolume:
22
Journal:
Breast Cancer Research
DOI:
10.1186/s13058-020-01303-9
Date:
December, 2020
Fichier:
PDF, 4.69 MB
2020
File converter
Plus de résultats de recherche
More benefits 
